ArticleFrontiers in pharmacology2026
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nonalcoholic fatty liver disease (NAFLD) is one of the most prevalent chronic liver diseases worldwide, and the associated metabolic dysfunction may increase susceptibility to drug-induced liver injury (DILI). This study aimed to evaluate the hepatoprotective effects of the Methods: The antioxidant and anti-inflammatory activities of GSEA were evaluated Results: GSEA exhibited significant antioxidant and anti-inflammatory activities. Twenty-five blood-absorbed ingredients were tentatively identified as potentially bioactive, and the PI3K/Akt/FoxO1 signaling pathway was predicted as a pathway of GSEA against liver injury. Molecular docking further demonstrated favorable binding interactions between AKT1 and several major constituents, including sweroside, loganic acid, swertiamarin, and gentiopicroside. Conclusion: Collectively, these findings provide mechanistic evidence supporting the potential application of GSEA as a natural therapeutic agent for the prevention or treatment of liver injury associated with metabolic dysfunction and tetracycline exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.